secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001437749-22-014892
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase
--------------------------------------------------------------------------------

- Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.
- Amendment to compensation policy under Israeli law not approved: 2.5M for, 4.9M against.
- Equity plan amendment (increase by 400K shares) approved narrowly: 5.3M for, 4.5M against.
- PricewaterhouseCoopers ratified as independent auditor with 14.2M votes for.
- All six director nominees elected, with Arie Belldegrun receiving 7.5M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/0001437749-22-014892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/urgn20220610_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-014892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer